Circulating CD4+ FoxP3- CXCR5- CXCR3+ PD-1hi cells are elevated in active rheumatoid arthritis and reflect the severity of the disease

Int J Rheum Dis. 2021 Aug;24(8):1032-1039. doi: 10.1111/1756-185X.14170. Epub 2021 Jul 6.

Abstract

Objective: To examine the expression and clinical significance of circulating CD4+ FoxP3- CXCR5- CXCR3+ PD-1hi cells in rheumatoid arthritis (RA).

Methods: CD4+ FoxP3- CXCR5- CXCR3+ PD-1hi cells in peripheral blood of 35 patients with active RA, 17 with RA in stable remission, and 24 healthy controls were analyzed by flow cytometry. Serum IgG and circulating plasmablast percentages were measured and correlations with CD4+ FoxP3- CXCR5- CXCR3+ PD-1hi cells were systematically analyzed. Disease Activity Scale 28 (DAS28) scores were also calculated and correlation analysis with CD4+ FoxP3- CXCR5- CXCR3+ PD-1hi cells was conducted. The levels of CD4+ FoxP3- CXCR5- CXCR3+ PD-1hi cells were compared before and after disease-modifying anti-rheumatic drug treatment. Cytokine levels in plasma and cytokine secretion in CD4 cells were measured and their correlations with CD4+ FoxP3- CXCR5- CXCR3+ PD-1hi cells were further analyzed.

Results: The levels of CD4+ FoxP3- CXCR5- CXCR3+ PD-1hi cells in the peripheral blood of patients with active RA were significantly increased compared with healthy controls. CD4+ FoxP3- CXCR5- CXCR3+ PD-1hi cells in patients with active RA were positively correlated with serum IgG and DAS28 scores. CD4+ FoxP3- CXCR5- CXCR3+ PD-1hi cells were significantly decreased in patients after treatment. Plasma interleukin-10 concentrations and interleukin-10-positive CD4 cell percentages were significantly positively correlated with CD4+ FoxP3- CXCR5- CXCR3+ PD-1hi cell levels.

Conclusion: Circulating CD4+ FoxP3- CXCR5- CXCR3+ PD-1hi cells in patients with active RA are increased and could reflect the severity of the disease, which may play a potential role in the pathogenesis of RA.

Keywords: CXCR3; CXCR5; T cells; autoantibodies; rheumatoid arthritis.

MeSH terms

  • Antirheumatic Agents / therapeutic use
  • Arthritis, Rheumatoid / blood
  • Arthritis, Rheumatoid / diagnosis
  • Arthritis, Rheumatoid / drug therapy
  • Arthritis, Rheumatoid / immunology*
  • Biomarkers / blood
  • CD4 Lymphocyte Count
  • CD4-Positive T-Lymphocytes / drug effects
  • CD4-Positive T-Lymphocytes / immunology*
  • CD4-Positive T-Lymphocytes / metabolism
  • Case-Control Studies
  • Cells, Cultured
  • Flow Cytometry
  • Forkhead Transcription Factors / blood*
  • Humans
  • Immunoglobulin G / blood
  • Immunophenotyping
  • Interleukin-10 / blood
  • Interleukins / blood
  • Phenotype
  • Programmed Cell Death 1 Receptor / blood*
  • Receptors, CXCR3 / blood*
  • Receptors, CXCR5 / blood*
  • Remission Induction
  • Severity of Illness Index
  • Treatment Outcome

Substances

  • Antirheumatic Agents
  • Biomarkers
  • CXCR3 protein, human
  • CXCR5 protein, human
  • FOXP3 protein, human
  • Forkhead Transcription Factors
  • IL10 protein, human
  • Immunoglobulin G
  • Interleukins
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor
  • Receptors, CXCR3
  • Receptors, CXCR5
  • Interleukin-10
  • interleukin-21